Biotechnology Value Fund II, L.P. Increases Position in Eledon Pharmaceuticals to 2.7%

On May 15, 2026, Biotechnology Value Fund L.P. (BVF) and its affiliates filed an amended Schedule 13G regarding their holdings in Eledon Pharmaceuticals, Inc. (ELDN). As of March 31, 2026, Biotechnology Value Fund II, L.P. reported beneficial ownership of 2,057,090 shares, representing 2.7% of the company. Collectively, the reporting group, which includes BVF, BVF II, Biotechnology Value Trading Fund OS LP, and Mark N. Lampert, may be deemed to beneficially own 7,868,419 shares, or 9.99% of the outstanding common stock. This aggregate ownership is subject to a 9.99% beneficial ownership blocker applicable to their holdings of Series X and Series X1 Convertible Preferred Stock, as well as various Pre-Funded and Tranche A Warrants. The filing indicates that on March 30, 2026, the reporting persons received 1,336,101 shares through the exercise or conversion of warrants and preferred stock. The reporting persons have certified that these shares were not acquired for the purpose of changing or influencing the control of the issuer.